80 varieties transferred out of health insurance from 1 September (attached list)

Pharmaceutical network August 17th, recently, according to industry rumors, there are 80 varieties will be transferred out of provincial health insurance, September 1 to implement.
documents show that, in order to implement the National Health Insurance Administration", "the original provincial drug catalog in accordance with the provisions of the increase of Class B drugs, should be gradually digested within three years", a provincial health insurance bureau, the provincial Human Resources and Social Security Department identified the provincial supplementary drugs in 2020 transferred varieties.
Is now ready to transfer the work notice is as follows: the number of transfer: the province's original supplementary drugs, 28 (specific to dosage form, the same below) has been included in the 2019 version of the National Health Insurance Drug Catalog;
the transfer will be implemented from September 1, 2020, when the cost of the drugs transferred will no longer be paid by the provincial basic medical insurance, work injury insurance and maternity insurance and maternity insurance funds.
, the co-ordination areas should strictly implement the notification requirements to ensure smooth and smooth implementation.
medical insurance and work injury insurance agencies at all levels should update and maintain the information system drug database in a timely manner, and do a good job with the designated medical institutions docking.
designated medical institutions should do a good job in the communication and interpretation of insured patients.
in the implementation process of all places encountered important situations and problems, to timely report to the provincial health insurance bureau, the provincial human resources and social security department.
Saiber blue combing found that this amoxilin dichloroxilin, methadocin injection, lactic acid bacteria, Dingguier umbilical cord paste, compound Sichuan bay mother tablets, compound stone flakes, acetylcysteine eye drops and other varieties were transferred out of the province's health insurance on September 1.
official release has news, the local supplement catalog in accordance with the 442 principle digestion: data show that after the exclusion of the 19 version of the medical insurance varieties, the local still added nearly 3000 varieties, a total of 180 billion sales;
industry has a view that the elimination of local supplements, increase reimbursement restrictions, this change is still based on the clinical value of drugs as a starting point, enhance the National Health Insurance Agency for the health care directory control capacity.
at the same time for pharmaceutical companies, the core varieties into the national health insurance is more important.
varieties will take advantage of the east wind of health insurance? At present, including Gansu, Ningxia, Xinjiang, Guangxi, Zhejiang, including a total of 20 provinces to implement the local supplementary directory out, of which, Tibet, Yunnan, Hebei, Shanghai, Anhui and other provinces announced before July 1, 2020, the list of transfer out;
in addition to a number of varieties out of medical insurance, the national medical insurance has also established a sound dynamic adjustment mechanism, in principle, once a year adjustment.
September 1, the "Interim Measures for the Administration of Basic Medical Insurance Drugs" officially came into effect, it is understood that tonics, health care products, vaccines, etc. are not included in the catalog, the relevant departments listed in the negative list of drugs will be transferred out of the catalog, the price or cost of enterprises without reasonable reasons for drugs, clinical value is not accurate can be better replaced drugs can also be transferred out of the catalog.
the same time, the National Health Insurance Administration issued the "2020 National Health Insurance Drug Catalog Adjustment Work Programme (Draft for Comments)" for public comments.
highlight of the draft is the inclusion of more innovative drugs, including domestically produced and imported.
, for example, articles 3, 5 and 7 of the seven new categories of medicines to be added are prescribed for innovative drugs.
from the 2019 health insurance catalog adjustment, can be seen at first sight: the 2019 version of the health insurance catalog transferred a total of 158 varieties, transferred 140 varieties, transferred into the variety of more new drugs.
Some research institutions analysis, to the 2017 and 2019 version of the health insurance catalog, for example, the adjustment of the health insurance catalog is conducive to the adjustment of the drug structure, compared to the 17 version of the medical insurance catalog, 19 years of catalog transfer into the variety involved a small amount, but the growth rate is faster, the transfer into the variety in 2018 reached 14 billion sales.
from the transfer of varieties, compared to the 17 version, 19 years of the amount involved is 20 times higher, the transfer of varieties in 2018 sales of 38.5 billion.
at an average annual rate of 30 per cent, it would free up $20 billion in space within three years.
under the introduction of many health insurance policies, the trend of health insurance funds constantly changing cages for birds has been finalized, China's market share of innovative drugs is expected to continue to rise, is expected to rise to 25% in 2022.
health insurance, the release effect is obviously included in health insurance, will promote the rapid release of varieties, there is no doubt about this.
, Ping An Securities data show that the health insurance fund is still the main payer of china's health expenditure.
In 2018, China's total health expenditure will be about 5.8 trillion yuan, of which the government will spend 1.64 trillion yuan (28 percent), social health will spend 2.49 trillion yuan (43 percent), and personal health spending will be 1.67 trillion yuan (29 percent).
social health expenditure is mainly the expenditure of health insurance fund, so health insurance is still the main payer of health expenditure in china.
Take Lilaglutide as an example, its 2017 through negotiations to include health insurance to achieve high-speed release, Lilaglutide's original drug companies are No and Nordism, the variety was listed in China in October 2011, because of high pricing, before entering the domestic market is not large, into health insurance, began to achieve rapid release, sales and sales growth in the current quarter reached 72% and 225%, respectively, significantly higher than before.
A year to date, belong to the first batch of national key monitoring drug catalog varieties all transferred out of the national health insurance, the provinces also transferred it out of local health insurance, by Ping An Securities estimates, 20 monitoring catalog varieties sales in about 65.3 billion yuan, with some varieties were moved out of the health insurance catalog, the cancellation of additional, will release a large number of health insurance funds.
today, enterprises to immediately assess the product line, if you want to achieve the release, to local addition of "curve to save the country" is no ready possible, the core varieties into the national health insurance directory is the most important.
.